A Phase 2/3 interventional study of UC-MSC-Derived Secretome and Sodium Hyaluronate (Hyalein) in Knee Osteoarthritis (Knee OA), sponsored by Universitas Sriwijaya. Not yet recruiting at 1 site in Indonesia. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by Universitas Sriwijaya · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing Hyaluronic Acid in Osteoarthritis, Knee — 4 open to participants now, 4 under way, 2 of them phase 3. Hyaluronic Acid · Osteoarthritis, Knee.
Among the 18 studies testing Hyaluronic Acid in Osteoarthritis, Knee, this one is the 10th largest by planned enrollment, is one of 3 that started in 2026, is one of 3 in phase 2/3, and was the 16th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →4 of the 18 studies testing Hyaluronic Acid in Osteoarthritis, Knee are open now, in 4 countries. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 50+
Phramongkutklao College of Medicine and Hospital · Sites in Thailand
Ages 50+
Universiti Sains Malaysia · Sites in Malaysia
Ages 40–70
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 40 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 6 · Phase 4 6
First in 2006; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 50 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 55 across the 18 interventional studies. Of the 12 that completed or were terminated, 2 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 18 have an industry lead sponsor. The 10 most frequent:
Universitas Sriwijaya is the lead sponsor of 20 studies on the registry; 2 are open to participants now.
Universitas Sriwijaya has 2 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
1 of the studies testing Hyaluronic Acid in Osteoarthritis, Knee that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07666347Tanta UniversityIntraarticular Injection of Botox and Hyaluronic Acid in Knee Osteoarthritis | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing Hyaluronic Acid in Osteoarthritis, Knee, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a randomized, double-blind, multicenter Phase II/III clinical trial designed to evaluate the effectiveness and safety of umbilical cord-derived mesenchymal stem cell (UC-MSC) secretome compared with sodium hyaluronate in patients with knee osteoarthritis. Knee osteoarthritis is a common degenerative joint disease that causes chronic pain and functional limitation. Participants will be randomly assigned to receive intra-articular injections of either UC-MSC-derived secretome or sodium hyaluronate. The study aims to assess improvements in knee pain, physical function, and overall clinical outcomes, as well as to evaluate the safety of the interventions over the study period.
This multicenter, randomized, double-blind Phase II/III clinical study aims to compare the efficacy and safety of intra-articular UC-MSC-derived secretome with sodium hyaluronate in patients with Kellgren-Lawrence grade 2-3 knee osteoarthritis. Eligible participants will be randomly allocated to one of two treatment arms. Clinical outcomes will be evaluated using validated pain and functional assessment tools at predefined time points. Safety assessments will include monitoring of adverse events throughout the study period. The results of this study are expected to provide evidence regarding the potential role of UC-MSC-derived secretome as an alternative therapeutic option for knee osteoarthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive intra-articular injection of UC-MSC-derived secretome
Drug: Sodium Hyaluronate (Hyalein)
Participants receive intra-articular injection of sodium hyaluronate
Biological: UC-MSC-Derived Secretome
Umbilical cord-derived mesenchymal stem cell secretome administered via intra-articular injection according to the study protocol.
Sodium hyaluronate administered via intra-articular injection as an active comparator.
Also known as: Sodium Hyaluronate
Change From Baseline in WOMAC Pain Subscale Score
Change from baseline in knee pain assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale.
Time frame: Baseline to Week 24
Change From Baseline in WOMAC Total Score
Change from baseline in overall knee pain, stiffness, and physical function assessed using WOMAC total score.
Time frame: Baseline to Week 12
Plan to share: Yes — De-identified individual participant data underlying the primary and secondary outcome measures, including demographic characteristics, baseline clinical data, outcome scores, and adverse event data, will be shared. All data will be fully anonymized, with no direct identifiers, in accordance with applicable ethical and regulatory requirements.
Supporting information: Study protocol, Statistical analysis plan
Time frame: De-identified individual participant data and supporting documents will be available beginning 6 months after publication of the primary study results and will remain available for up to 5 years.
Access criteria: Access to de-identified IPD will be granted to qualified researchers who submit a methodologically sound research proposal. Requests will be reviewed by the study steering committee. Data will be shared under a data use agreement to ensure participant confidentiality and appropriate use of the data.
Data sharing details ↗ · rsmh.go.id
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Sep 2026, 0 months later.
Of 18 phase 2/3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 0 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hyaluronic Acid
Universitas Sriwijaya